Ranitidine: Difference between revisions
No edit summary |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (7 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: H2 | *Type: [[H2 blocker]] | ||
*Dosage Forms: | *Dosage Forms: 75mg, 150mg, 300mg | ||
*Common Trade Names: Zantac | *Common Trade Names: Zantac | ||
==Adult Dosing== | ==Adult Dosing== | ||
GERD: | GERD: 150mg PO BID | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
GERD: 5- | GERD: 5-10mg/kg/day PO BID | ||
==Special Populations== | ==Special Populations== | ||
| Line 14: | Line 14: | ||
*Lactation: Probably Safe | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult: CrCl < 50: | **Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis | ||
**Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | **Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | ||
*Hepatic Dosing | *Hepatic Dosing | ||
| Line 47: | Line 47: | ||
*Excretion: Urine, Feces | *Excretion: Urine, Feces | ||
*Mechanism of Action: H2 blocker | *Mechanism of Action: H2 blocker | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Ranitidine]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category: | |||
[[Category:Pharmacology]] | |||
Latest revision as of 21:56, 20 March 2026
General
- Type: H2 blocker
- Dosage Forms: 75mg, 150mg, 300mg
- Common Trade Names: Zantac
Adult Dosing
GERD: 150mg PO BID
Pediatric Dosing
GERD: 5-10mg/kg/day PO BID
Special Populations
- Pregnancy Rating: B
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis
- Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis
- Hepatic Dosing
- Adult: Not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Porphyria
- Caution if impairment of liver or kidneys
- Caution in chronic pulmonary disease
- Caution if diabetes mellitus
- Caution if immunocompromised
Adverse Reactions
Serious
- Thrombocytopenia
- Hepatotoxicity
- Pneumonia
Common
- Nausea/vomiting/diarrhea
- Fatigue
- Headache
- Rash
- Myalgia
- Xerostomia
Pharmacology
- Half-life: 2-3 hr, Renal impairment: 5 hr
- Metabolism: Liver
- Excretion: Urine, Feces
- Mechanism of Action: H2 blocker
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.